Cost Management Insights: SG&A Expenses for Axsome Therapeutics, Inc. and Novavax, Inc.

Navigating SG&A Expenses: A Tale of Two Biotechs

In the dynamic world of biotechnology, managing costs is crucial for survival and growth. Axsome Therapeutics, Inc. and Novavax, Inc. offer a fascinating study in contrasts over the past decade. From 2014 to 2023, Axsome's Selling, General, and Administrative (SG&A) expenses skyrocketed by over 23,000%, reflecting its aggressive expansion and strategic investments. Meanwhile, Novavax's SG&A expenses surged by approximately 2,300%, underscoring its commitment to scaling operations amid the global vaccine race.

Key Insights

• Axsome's Growth: Starting with modest expenses in 2014, Axsome's SG&A costs peaked in 2023, highlighting its rapid growth trajectory.
• Novavax's Strategy: Novavax maintained a steady increase, with a notable spike in 2020, aligning with its pivotal role in COVID-19 vaccine development.

These trends underscore the importance of strategic cost management in the biotech sector, where innovation and agility are paramount.